{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:31:01Z","timestamp":1779114661974,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.10.095","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T08:38:57Z","timestamp":1605256737000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart"],"prefix":"10.1016","volume":"39","author":[{"given":"Jeffry D.","family":"Shearer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Henning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario H.","family":"Skiadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Ionin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6458-2690","authenticated-orcid":false,"given":"Vladimir","family":"Savransky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2020.10.095_b0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg"},{"issue":"11","key":"10.1016\/j.vaccine.2020.10.095_b0010","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1128\/AAC.00090-06","article-title":"Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model","volume":"50","author":"Kao","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.095_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6804a1","article-title":"Use of anthrax vaccine in the United States: recommendations of the advisory committee on immunization practices, 2019","volume":"68","author":"Bower","year":"2019","journal-title":"MMWR Recomm Rep"},{"issue":"3","key":"10.1016\/j.vaccine.2020.10.095_b0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14760584.5.3.365","article-title":"CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine","volume":"5","author":"Klinman","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.095_b0025","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1074-7613(00)80256-3","article-title":"Immune activation by bacterial DNA: a new genetic code","volume":"5","author":"Pisetsky","year":"1996","journal-title":"Immunity"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2020.10.095_b0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0264-410X(99)00316-3","article-title":"Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines","volume":"18","author":"Kim","year":"1999","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2020.10.095_b0035","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax(R) (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"issue":"37","key":"10.1016\/j.vaccine.2020.10.095_b0040","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1016\/j.vaccine.2017.07.076","article-title":"Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate","volume":"35","author":"Savransky","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.095_b0045","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"RR-6","key":"10.1016\/j.vaccine.2020.10.095_b0050","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the advisory committee on immunization practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep."},{"issue":"151","key":"10.1016\/j.vaccine.2020.10.095_b0055","doi-asserted-by":"crossref","first-page":"151ra26","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.vaccine.2020.10.095_b0060","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/14760584.2016.1254556","article-title":"Licensure strategy for pre- and post-exposure prophylaxis of Biothrax vaccine: the first vaccine licensed using the FDA animal rule","volume":"15","author":"Longstreth","year":"2016","journal-title":"Expert Rev Vaccines"},{"issue":"18","key":"10.1016\/j.vaccine.2020.10.095_b0065","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.vaccine.2016.03.006","article-title":"Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults","volume":"34","author":"Hopkins","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.095_b0070","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1128\/IAI.01289-12","article-title":"Pathology and pathophysiology of inhalational anthrax in a guinea pig model","volume":"81","author":"Savransky","year":"2013","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2020.10.095_b0075","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/01.LAB.0000080599.43791.01","article-title":"Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis)","volume":"83","author":"Vasconcelos","year":"2003","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.095_b0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1152\/ajplegacy.1947.150.1.70","article-title":"Measurement of the respiratory volumes of laboratory animals","volume":"150","author":"Guyton","year":"1947","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.095_b0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/15287398509530647","article-title":"Comparative deposition of inhaled aerosols in experimental animals and humans: a review","volume":"15","author":"Schlesinger","year":"1985","journal-title":"J Toxicol Environ Health"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2020.10.095_b0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"issue":"3","key":"10.1016\/j.vaccine.2020.10.095_b0095","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.coviro.2012.01.004","article-title":"Licensure of vaccines using the Animal Rule","volume":"2","author":"Burns","year":"2012","journal-title":"Curr Opin Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.095_b0100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/108729001753231713","article-title":"CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved","volume":"11","author":"Rankin","year":"2001","journal-title":"Antisense Nucl Acid Drug Dev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2031433X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2031433X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:49:34Z","timestamp":1759402174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2031433X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X2031433X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.095","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}